What's Happening?
ACIST Medical Systems, a subsidiary of Bracco, has announced the U.S. Food and Drug Administration (FDA) clearance for its ACIST Pro Diagnostic System. This next-generation system is designed to enhance precision, safety, and efficiency in image-guided
cardiovascular procedures. The ACIST Pro System builds on the company's previous technology, ACIST CVi, which automated contrast delivery in cardiac catheterization labs. The new system offers variable-rate contrast management, reducing contrast use and procedure time while improving patient outcomes. The system was first introduced in Japan in 2025 and has since been launched in select European markets. The U.S. launch marks a significant milestone for the company, aiming to support clinicians with more informed diagnostic decisions.
Why It's Important?
The FDA clearance of the ACIST Pro Diagnostic System is a pivotal development in the field of interventional cardiology. By providing a more precise and efficient method for contrast delivery, the system has the potential to improve patient outcomes and streamline procedures in cath labs across the U.S. This advancement is particularly important as it addresses the need for reducing contrast-induced acute kidney injury (CI-AKI) and procedure times, which are critical factors in patient care. The introduction of this technology in the U.S. market underscores the ongoing innovation in medical imaging and the commitment to enhancing healthcare delivery. It also reflects the broader trend of integrating advanced technologies to improve clinical practices and patient safety.
